Results 241 to 250 of about 18,386 (273)
Plenary Abstracts Session & Oral Presentations
HemaSphere, Volume 10, Issue S1, June 2026.
wiley +1 more source
, 2021 Cardiovascular diseases (CVDs) are the number one cause of death globally. In 2012, 17.5 million people died of CVDs, of which 43% were caused by ischemic heart disease and 38% by stroke. Thrombosis plays a pivotal role in the development of ischemic heart disease and stroke. Therefore, the haemostatic system has been one of the main targets of prevent
Kremers, Romy
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Thrombin allosteric modulation revisited: a molecular dynamics study
Journal of Molecular Modeling, 2009The regulatory properties of thrombin are derived predominantly from its capacity to produce different functional conformations. Functional studies have revealed that two antagonistic thrombin conformations exist in equilibrium: the fast (procoagulant) and slow (anticoagulant) forms.
Hermes Luís Neubauer DE AMORIM +2 more
exaly +3 more sources
Thrombin - A Molecular Dynamics Perspective
Mini-Reviews in Medicinal ChemistryAbstract: Thrombin is a crucial enzyme involved in blood coagulation, essential for maintaining circulatory system integrity and preventing excessive bleeding. However, thrombin is also implicated in pathological conditions such as thrombosis and cancer.
Freddie R Salsbury, Jiajie Xiao
exaly +3 more sources
Biophysics (Russian Federation), 2013
Thrombin is a major component of blood clotting and involved in the formation of a fibrin clot. One of the precursors during thrombin maturation is prethrombin-2, with the presence of Arg363-Ile364 bond between the light and heavy chain of protein, the only distinction from thrombin.
Veselovsky A V
exaly +4 more sources
Thrombin is a major component of blood clotting and involved in the formation of a fibrin clot. One of the precursors during thrombin maturation is prethrombin-2, with the presence of Arg363-Ile364 bond between the light and heavy chain of protein, the only distinction from thrombin.
Veselovsky A V
exaly +4 more sources
Molecular dynamics simulations of thrombin inhibitors at the S' subsites of thrombin.
Drug design and discovery, 1994 Molecular dynamics were carried out to simulate binding interactions between S' subsites of thrombin and hirudin-based thrombin inhibitors. These inhibitors include three segments: an active-site segment, N alpha-acetyl-(D-Phe)-Pro-Arg-Pro-; a fibrinogen-recognition exo-site segment, hirudin 55-65; and a 13-atom-long linker.
Yue, S. Y., Konishi, Y.
openaire +3 more sources
Dynamics of clot growth induced by thrombin diffusing into nonstirred citrate human plasma
Biochimica Et Biophysica Acta - General Subjects, 1998The dynamics of clot formation was studied in a two-compartment chamber designed to allow free diffusion of thrombin according to its concentration gradient into nonstirred citrate plasma or fibrinogen solution. Fibrin clots in fibrinogen solutions increased progressively until the substrate was depleted.
Elena I Sinauridze, F I Ataullakhanov
exaly +3 more sources